Hungary’s Egis Pharmaceuticals has bolstered its OTC portfolio in its domestic market with the acquisition of skin-care brand Neogranormon from Teva Pharmaceutical Industries for an undisclosed sum.
The acquired Neogranormon portfolio is led by a zinc oxide-based ointment approved as an OTC drug in Hungary, which is said by Egis to stimulate the healing of skin injuries while protecting against the risk of infection